Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04561362 | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 329 | BicycleTx LimitedINDUSTRY | 6 | Nov 14, 2025 | clinicaltrials |
| NCT05661461 | Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | recruiting | Phase 1 | 28 | Aadi Bioscience, Inc.INDUSTRY | 1 | Nov 13, 2025 | clinicaltrials |
| NCT03486301 | BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab(EIK1001) | completed | Phase 1 | 87 | Eikon TherapeuticsINDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04196530 | BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab(EIK1001) | completed | Phase 1 | 40 | Eikon TherapeuticsINDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04840394 | Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | completed | Phase 1 | 1 | Eikon TherapeuticsINDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | active not recruiting | Phase 1 / Phase 2 | 70 | Dan ZandbergOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 82 | Nuvation Bio Inc.INDUSTRY | 2 | Nov 6, 2025 | clinicaltrials |
| NCT06504368 | Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors | recruiting | Phase 1 | 32 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Nov 6, 2025 | clinicaltrials |
| NCT07055594 | A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors(NbTAST-01) | recruiting | Phase 1 / Phase 2 | 76 | Shine-On Biomedical Co., Ltd.INDUSTRY | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03396445 | Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | completed | Phase 1 | 182 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Nov 5, 2025 | clinicaltrials |
| NCT05322408 | HCW9218 in Select Advanced Solid Tumors | completed | Phase 1 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05847686 | Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer | completed | Phase 1 / Phase 2 | 55 | University of WashingtonOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT03770494 | A Study of LY3405105 in Participants With Advanced Cancer | terminated | Phase 1 | 54 | Eli Lilly and CompanyINDUSTRY | 5 | Nov 4, 2025 | clinicaltrials |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 200 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT07224568 | Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors(INTERCEPT) | not yet recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT04643418 | Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 81 | MegaPro Biomedical Co. Ltd.INDUSTRY | 1 | Nov 3, 2025 | clinicaltrials |
| NCT04972110 | Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors(ATTACC) | terminated | Phase 1 / Phase 2 | 156 | Repare TherapeuticsINDUSTRY | 1 | Oct 30, 2025 | clinicaltrials |
| NCT03010176 | Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) | completed | Phase 1 | 156 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Oct 29, 2025 | clinicaltrials |
| NCT05029882 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | active not recruiting | Phase 1 | 520 | AbbVieINDUSTRY | 10 | Oct 29, 2025 | clinicaltrials |
| NCT05205330 | Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | active not recruiting | Phase 1 / Phase 2 | 107 | Rottapharm BiotechINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT05597839 | Study of DF9001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 24 | Dragonfly TherapeuticsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT06249048 | Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | recruiting | Phase 1 / Phase 2 | 108 | Strand Therapeutics Inc.INDUSTRY | 2 | Oct 29, 2025 | clinicaltrials |
| NCT06228326 | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs(KYANITE-1) | recruiting | Phase 1 / Phase 2 | 250 | Krystal Biotech, Inc.INDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT02597036 | A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors | terminated | Phase 1 | 62 | Eli Lilly and CompanyINDUSTRY | 4 | Oct 23, 2025 | clinicaltrials |
| NCT04185883 | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | active not recruiting | Phase 1 | 610 | AmgenINDUSTRY | 13 | Oct 22, 2025 | clinicaltrials |
| NCT02711137 | Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 137 | Incyte CorporationINDUSTRY | 3 | Oct 21, 2025 | clinicaltrials |
| NCT02959437 | Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | terminated | Phase 1 / Phase 2 | 70 | Incyte CorporationINDUSTRY | 3 | Oct 21, 2025 | clinicaltrials |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | terminated | Phase 1 | 25 | Incyte CorporationINDUSTRY | 2 | Oct 21, 2025 | clinicaltrials |
| NCT04497116 | Study of RP-3500, Camonsertib, in Advanced Solid Tumors(TRESR) | completed | Phase 1 / Phase 2 | 276 | Repare TherapeuticsINDUSTRY | 4 | Oct 21, 2025 | clinicaltrials |
| NCT02159989 | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2025 | clinicaltrials |
| NCT02680795 | Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes | completed | Phase 1 | 17 | Acrotech Biopharma Inc.INDUSTRY | 1 | Oct 20, 2025 | clinicaltrials |
| NCT03889795 | Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors | active not recruiting | Phase 1 | 15 | Danae Hamouda, MDOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05627063 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 169 | Abbisko Therapeutics Co, LtdINDUSTRY | 2 | Oct 20, 2025 | clinicaltrials |
| NCT05646797 | A Study of ASP2074 in Adults With Solid Tumors | terminated | Phase 1 | 23 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Oct 20, 2025 | clinicaltrials |
| NCT05859464 | A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 34 | Zai Lab (Hong Kong), Ltd.INDUSTRY | 3 | Oct 20, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT05082610 | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors | completed | Phase 1 | 48 | Hummingbird BioscienceINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05639751 | PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation | completed | Phase 1 | 135 | Prelude TherapeuticsINDUSTRY | 5 | Oct 16, 2025 | clinicaltrials |
| NCT02512926 | Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children(POE14-01) | completed | Phase 1 | 4 | Stanford UniversityOTHER | 2 | Oct 15, 2025 | clinicaltrials |
| NCT06336148 | A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 10 | Actym Therapeutics, Inc.INDUSTRY | 2 | Oct 15, 2025 | clinicaltrials |
| NCT04982926 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | terminated | Phase 1 | 29 | Taiho Oncology, Inc.INDUSTRY | 2 | Oct 14, 2025 | clinicaltrials |
| NCT05293496 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | completed | Phase 1 | 31 | MacroGenicsINDUSTRY | 1 | Oct 14, 2025 | clinicaltrials |
| NCT06644170 | A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer | completed | Phase 1 | 15 | University of WashingtonOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT05948826 | First in Human Study of TORL-3-600 in Participants With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT03522142 | A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies | terminated | Phase 1 | 83 | Incyte CorporationINDUSTRY | 5 | Oct 9, 2025 | clinicaltrials |
| NCT04370587 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | ImmVira Pharma Co. LtdINDUSTRY | 2 | Oct 8, 2025 | clinicaltrials |
| NCT04362748 | Study of AMG 256 in Adult Subjects With Advanced Solid Tumors | completed | Phase 1 | 34 | AmgenINDUSTRY | 4 | Oct 7, 2025 | clinicaltrials |
| NCT04954599 | Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | recruiting | Phase 1 / Phase 2 | 126 | Maastricht University Medical CenterOTHER | 3 | Oct 7, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Nov 14, 2025source: clinicaltrials